GuidelinesOther guideline
Circular 22 January 2025: Anastrozole Availability and Therapeutic Alternative
The Tertiary and Quaternary Essential Medicines List (EML) recommends the use of the aromatase inhibitors for the management of adjuvant and metastatic breast cancer. The aromatase inhibitors recommended are: anastrozole, letrozole and exemestane. See table below outlining the NEMLC recommendation. Click here to access the circular .
The Tertiary and Quaternary Essential Medicines List (EML) recommends the use of the aromatase inhibitors for the management of adjuvant and metastatic breast cancer. The aromatase inhibitors recommended are: anastrozole, letrozole and exemestane. See table below outlining the NEMLC recommendation.